Compare Monolithic Power Systems Inc (MPWR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Neurocrine Biosciences Inc — how do they compare? Monolithic Power Systems Inc trades at $1,415 (market cap $67.87B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Monolithic Power Systems Inc is far larger — about 4× Neurocrine Biosciences Inc's market cap, and Monolithic Power Systems Inc pays a 0.58% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MPWR | NBIX | |
|---|---|---|
Market Cap | $67.87B | $16.76B |
Sector | Utilities | Health |
52-Week High | $1.69K | $185.50 |
52-Week Low | $820.74 | $123.10 |
Enterprise Value | $66.48B | $16.78B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,401.54, up 3.12% today, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, supported by robust fundamentals including 24.5% net income margin and 21.98% ROE. Recent Q2 2026 results showed EPS of $6.50, exceeding estimates, with revenue growth driven by AI infrastructure demand. Analyst sentiment remains overwhelmingly positive with 88% buy ratings.
The outlook for MPWR is favorable due to accelerating AI-driven revenue and expanding margins, though high valuation multiples (P/E 84.26) pose a risk if growth slows. Investor optimism is tempered by potential overvaluation and sensitivity to tech sector volatility. The consensus price target of $1,870 suggests upside, but execution risks and competitive pressures warrant caution.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
